Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML

This phase II trial tests how well VA alternating with low-dose CHA works in treating unfit patients with newly diagnosed acute myeloid leukemia (AML). This is a prospective, multi-centers, single arm phase II study aimed to overcome VEN resistance and achieve greater MRD negative rate, providing better control of treatment for unfit AML.

Trial Details

NCT ID
NCT07172204
Phase
PHASE2
Sponsor
First Affiliated Hospital of Zhejiang University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Alternately treated with VA/low CHA regimen
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Shenzhen, Guangdong, China|22.54554,114.0683
  • Suzhou, Jiangsu, China|31.30408,120.59538
  • Nanchang, Jiangxi, China|28.68396,115.85306
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Understand the research and sign a written informed consent form;
  • Be newly diagnosed with AML according to WHO 2022 criteria without prior treatment;
  • or unwilling to undergo IC. Ineligibility for IC is defined as meeting any of the following criteria:
  • Age ≥ 60 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →